Moreover, IFN-β-engineered BM-MSCs can selectively home to locations of primary and metastatic pancreatic cancers, regulating TME and reducing the growth of pancreatic cancer [96]. The gene discussed is IFNB1; the disease is familial pancreatic carcinoma.